Dr. Aharon Schwartz has been with Teva since 1975 and is currently VP Strategic Business Planning and New Ventures. Prior to that he served as VP  Global Products Division, VP of the Copaxone® Division, VP Business Development/Export Division and head of the Pharmaceutical Division . He received his Ph.D. in Chemistry from the Weizmann Institute.

Mr. Goldberg is Vice president of CBI and he serves on a number of industry boards contributing his expertise in the field. In his former position as technology analyst and equity funds manager for a top Israeli mutual funds management company, Mr. Goldberg managed equity funds with a total asset value of $200M. As a graduate of the IDF's prestigious Talpiot project, he brings hands-on expertise in R&D and project management. Mr. Goldberg received an M.A. in Economics and Finance from the Tel Aviv University and a B.Sc. in Physics and Mathematics from the Hebrew University of Jerusalem..

Mr. Bianco served over 18 years as the CFO of Agis Industries Ltd and from 2001 to 2003 as CEO. Throughout his employment with Agis, Mr. Bianco actively participated in transforming Agis into an internationally known pharmaceutical company with revenues of more than $350 million. In 1992, as Agis' CFO, Mr. Bianco helped lead the company's IPO on the Tel Aviv Stock Exchange. He currently serves as a Director at BiolineRx, Mazor Surgical Technologies, Optimata Ltd, Fischer Pharmaceutical Labs, HealOr Ltd and Sol-Gel Technologies Ltd. Mr. Bianco received his B.A. in Economics and Accounting from Tel-Aviv University.

Anat Benish has served as Chairman and Director of various companies including, amongst others, Psagot Compass Investments Ltd, Psagot Exchange Traded Notes Group, Psagot Insurance Agencies Investments Ltd and Long-term Savings Clearing House Ltd. Ms. Benish served as V.P. of Information Systems, Operations and H.R. at Psagot Investment House Ltd and served for many years as CFO at Psagot Mutual Funds Ltd. She also served as senior tax controller at the Israel Tax Authority of the Ministry of Finance. Ms. Benish received an MBA from Heriot-Watt University Edinburgh, a CPA license in 1992 and a B.Sc. in Mathematics and Accounting from Tel Aviv University.

Dr. Molcho has been a venture partner at Forbion Capital Partners since 2007. Prior to that, from 2001 he was a managing director at Giza Venture Capital. Dr. Molcho is a cofounder of BiolineRX, a founder of Biologic Design and he serves on the Boards of Pathway Medical Inc. and Circulite Inc. Trained in psychiatry and psychopharmacology, Dr. Molcho served as Deputy Director General of The Abarbanel Mental Health Center, and headed of the residency program at Tel Aviv University Medical School. He was also the chief editor of the Israel National Boards of Psychiatry. Dr. Molcho was awarded his MD and MBA from Tel Aviv University and served as the Chief Medical Officer of the Naval Commando (Navy Seals) of the Israeli Defense Forces (IDF).

Ron Kenett has over 25 years of experience in restructuring and improving the competitive position of organizations by integrating statistical methods, process analysis, supporting technologies and modern human resource management systems. He is Chairman and CEO of the KPA Group, International Research Professor at the Center for Risk Engineering, NYU-Poly, USA and Research Professor at the University of Torino, Italy. Previously, he was Professor of Management at the State University of New York, Director of Statistical Methods for Tadiran Telecommunications Corporation and Member of the Technical Staff at Bell Laboratories in New Jersey. He has a Ph.D. in Mathematics from the Weizmann Institute of Science, and a B.Sc. in Mathematics from Imperial College of Science and Technology. Ron has published extensively on statistical applications in the life science, industrial and business domains including books on Modern Industrial Statistics, Multivariate Quality Control, Process Improvement in Systems and Software Development and Operational Risk Management. He has been a consultant to major pharmaceutical companies in the area of Quality by Design, Biostatistics and Risk Management. Ron is active in supporting start-up companies in Israel and Italy and was one of the founders of the publicly traded company Babylon.